following an abbreviated submission:
atogepant (Aquipta®) is accepted for restricted use within NHSScotland.
Indication under review: for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
SMC restriction: for patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments.
Atogepant provides an additional treatment choice in the therapeutic class of calcitonin gene-related peptide (CGRP) inhibitors.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice275KB (PDF)
- Medicine name:
- atogepant (Aquipta)
- SMC ID:
Prophylaxis of migraine in adults who have at least four migraine days per month.
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published
- 09 October 2023